A Clinical Study Investigating the Effects of a Dentifrice Containing 67% Sodium Bicarbonate When Used Twice Daily for 12 Weeks on Gingivitis Treatment and Plaque Removal

Exclusion criteria

• . A participant using any antibiotic medication within 14 days prior to screening or at any time during the study.
• . A participant currently taking an anti-inflammatory medication which, in the opinion of the Investigator, could affect gingival condition.
• . A participant currently taking a systemic medication (such as, anti-inflammatory, anticoagulant, immunosuppressants) or traditional/ herbal remedy which, in the opinion of the Investigator, could affect plaque/ gingival condition (such as, ibuprofen, aspirin, warfarin, cyclosporin, phenytoin, calcium channel blockers).
• . A participant who has taken (in the previous 14 days), any antibiotics.
• . A participant who has taken (in the previous 14 days) a systemic medication (such as, anti-inflammatory, anti-coagulant, immunosuppressants) or traditional/ herbal remedy which, in the opinion of the Investigator, could affect plaque/ gingival condition (such as, ibuprofen, aspirin, warfarin, cyclosporin, phenytoin, calcium channel blockers).
• . A participant who has used an antibacterial dentifrice or mouthwash (such as, chlorhexidine) or any oral care product that in the view of the investigator could interfere with plaque formation or measures of gingivitis, in the period between Screening and the Baseline visit.
• . A participant who shows signs of periodontitis (one or more sites with probing pocket depths more than \[\>\] 3 mm).
• . A participant who is receiving or has received treatment for periodontal disease (including surgery) within 12 months of Screening.